Opendata, web and dolomites

CANCERSCREEN SIGNED

Screening for cancer in the post-genomic era: diagnostic innovation and biomedicalisation in comparative perspective

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CANCERSCREEN project word cloud

Explore the words cloud of the CANCERSCREEN project. It provides you a very rough idea of what is the project "CANCERSCREEN" about.

health    quantitative    human    fuel    1996    screening    private    redrawing    decision    freight    diagnostics    surrounding    alia    biomedicine    integrative    usa    unprecedented    domain    insights    anecdote    sickness    tests    gene    public    literature    shaping    map    disease    expert    genomic    technological    first    innovative    age    platform    scientometric    diagnostic    molecular    theory    paucity    linking    qualitative    scholarship    transnational    technologies    industry    continue    innovation    integration    examine    genome    interactions    economy    monopolies    detection    inter    patenting    categories    deliberation    political    boundaries    model    trajectories    actors    risks    cancer    revolution    regulation    generation    harms    combining    dimensions    socio    empirical    expectations    accompanied    investments    steer    data    regime    policy    transition    regulatory    opinion    day    biomedicalisation    decade    reconfiguring    conceptual    dynamics   

Project "CANCERSCREEN" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 1˙347˙992 €
 EC max contribution 1˙347˙992 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-04-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 1˙047˙674.00
2    THE UNIVERSITY OF SUSSEX UK (BRIGHTON) participant 300˙317.00

Map

 Project objective

Cancer screening and the diagnostics industry: a comparative analysis of the political economy of diagnostic innovation A decade after the Human Genome Project, major public and private investments continue to fuel expectations of a genomic revolution in biomedicine. The freight of expectations surrounding the new “age of diagnostics” is accompanied by much uncertainty about how public policy should steer diagnostic innovation, with much debate about inter alia the harms of creating diagnostic monopolies through gene patenting, and the risks of under- or over-regulation. However, due to the paucity of research on diagnostic innovation, policy deliberation is driven more by anecdote and expert opinion than empirical evidence. With a specific focus on screening/early detection of cancer, this project will map industry dynamics, technological trajectories and regulatory developments in Europe and the USA from 1996 to the present day. Combining quantitative and qualitative methods, the project’s innovative dimensions include a new conceptual model of socio-technical transition in the diagnostics sector, and the first integrative analysis linking scientometric data on the interactions between public and private actors in the diagnostic research domain with comparative transnational analysis of regulatory decision-making. Through a novel integration of conceptual insights from the literature on biomedicalisation and scholarship on socio-technical regime change, this project aims to advance both fields of research by applying a new multi-scale, multi-level model of socio-technical transition. The project will provide unprecedented insight into the factors shaping the development of a new generation of molecular diagnostic tests, and examine how these technologies are reconfiguring disease categories and redrawing the boundaries between health and sickness. We will establish a platform of theory and methods for a broader programme of work on diagnostic innovation.

 Publications

year authors and title journal last update
List of publications.
2019 Kelly Holloway, Fiona A Miller, Alberto Gutierrez, Stuart Hogarth
Dangerous diagnostics? Regulatory reform in the genomic era
published pages: l640, ISSN: 0959-8138, DOI: 10.1136/bmj.l640
BMJ 2020-01-30
2019 Kelly Holloway, Fiona A. Miller, François Rousseau, Alberto Gutierrez, Stuart Hogarth
Health Canada needs to act on laboratory-developed diagnostics
published pages: E1067-E1069, ISSN: 0820-3946, DOI: 10.1503/cmaj.190550
Canadian Medical Association Journal 191/39 2020-01-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANCERSCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CANCERSCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CITISENSE (2019)

Evolving communication systems in response to altered sensory environments

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More  

MATCH (2020)

Discovering a novel allergen immunotherapy in house dust mite allergy tolerance research

Read More